CN109384767A - 一种吡啶并嘧啶类衍生物的制备方法及其中间体 - Google Patents
一种吡啶并嘧啶类衍生物的制备方法及其中间体 Download PDFInfo
- Publication number
- CN109384767A CN109384767A CN201810888327.5A CN201810888327A CN109384767A CN 109384767 A CN109384767 A CN 109384767A CN 201810888327 A CN201810888327 A CN 201810888327A CN 109384767 A CN109384767 A CN 109384767A
- Authority
- CN
- China
- Prior art keywords
- formula
- compound
- alkyl
- group
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 150000008518 pyridopyrimidines Chemical class 0.000 title abstract description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 73
- 238000006243 chemical reaction Methods 0.000 claims abstract description 26
- 238000000034 method Methods 0.000 claims abstract description 24
- 238000004519 manufacturing process Methods 0.000 claims abstract description 9
- -1 2, 4-dimethoxybenzyl Chemical group 0.000 claims description 29
- 125000000217 alkyl group Chemical group 0.000 claims description 21
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 20
- 125000003118 aryl group Chemical group 0.000 claims description 14
- 229910052736 halogen Inorganic materials 0.000 claims description 13
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 13
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 13
- 150000002367 halogens Chemical class 0.000 claims description 11
- 125000006239 protecting group Chemical group 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 9
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 8
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 8
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 7
- 229910052794 bromium Inorganic materials 0.000 claims description 7
- 229910052801 chlorine Inorganic materials 0.000 claims description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- 125000003282 alkyl amino group Chemical group 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 claims description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 5
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 5
- 229910052740 iodine Inorganic materials 0.000 claims description 5
- LZWQNOHZMQIFBX-UHFFFAOYSA-N lithium;2-methylpropan-2-olate Chemical compound [Li+].CC(C)(C)[O-] LZWQNOHZMQIFBX-UHFFFAOYSA-N 0.000 claims description 5
- 125000001424 substituent group Chemical group 0.000 claims description 5
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 claims description 5
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 claims description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 4
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims description 4
- 239000003054 catalyst Substances 0.000 claims description 4
- 229910052802 copper Inorganic materials 0.000 claims description 4
- 239000010949 copper Substances 0.000 claims description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 4
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 claims description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 4
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 claims description 3
- LVEYOSJUKRVCCF-UHFFFAOYSA-N 1,3-Bis(diphenylphosphino)propane Substances C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCP(C=1C=CC=CC=1)C1=CC=CC=C1 LVEYOSJUKRVCCF-UHFFFAOYSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 3
- 239000007810 chemical reaction solvent Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 3
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 3
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 3
- ZEMZPXWZVTUONV-UHFFFAOYSA-N 2-(2-dicyclohexylphosphanylphenyl)-n,n-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 ZEMZPXWZVTUONV-UHFFFAOYSA-N 0.000 claims description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims description 2
- MXFYYFVVIIWKFE-UHFFFAOYSA-N dicyclohexyl-[2-[2,6-di(propan-2-yloxy)phenyl]phenyl]phosphane Chemical compound CC(C)OC1=CC=CC(OC(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 MXFYYFVVIIWKFE-UHFFFAOYSA-N 0.000 claims description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052737 gold Inorganic materials 0.000 claims description 2
- 239000010931 gold Substances 0.000 claims description 2
- 239000012535 impurity Substances 0.000 claims description 2
- 229910052742 iron Inorganic materials 0.000 claims description 2
- 229940045996 isethionic acid Drugs 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 229910052759 nickel Inorganic materials 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 229910000073 phosphorus hydride Inorganic materials 0.000 claims description 2
- 229910052697 platinum Inorganic materials 0.000 claims description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 claims description 2
- 235000011009 potassium phosphates Nutrition 0.000 claims description 2
- 239000013558 reference substance Substances 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 239000001488 sodium phosphate Substances 0.000 claims description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 2
- VNFWTIYUKDMAOP-UHFFFAOYSA-N sphos Chemical compound COC1=CC=CC(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 VNFWTIYUKDMAOP-UHFFFAOYSA-N 0.000 claims description 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical compound NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 claims 1
- 239000003513 alkali Substances 0.000 claims 1
- 239000002994 raw material Substances 0.000 claims 1
- 239000000543 intermediate Substances 0.000 abstract description 7
- 238000003756 stirring Methods 0.000 description 17
- 125000000753 cycloalkyl group Chemical group 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 125000004432 carbon atom Chemical group C* 0.000 description 11
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 11
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 10
- 238000001914 filtration Methods 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 125000001072 heteroaryl group Chemical group 0.000 description 8
- 238000005406 washing Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- 238000005580 one pot reaction Methods 0.000 description 6
- 125000006413 ring segment Chemical group 0.000 description 6
- 235000002639 sodium chloride Nutrition 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 125000003545 alkoxy group Chemical group 0.000 description 5
- 229910052786 argon Inorganic materials 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 239000012065 filter cake Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000003541 multi-stage reaction Methods 0.000 description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 125000004414 alkyl thio group Chemical group 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 150000007942 carboxylates Chemical class 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 125000004093 cyano group Chemical group *C#N 0.000 description 4
- 125000000000 cycloalkoxy group Chemical group 0.000 description 4
- 125000005366 cycloalkylthio group Chemical group 0.000 description 4
- 125000001188 haloalkyl group Chemical group 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- ICGLPKIVTVWCFT-UHFFFAOYSA-N 4-methylbenzenesulfonohydrazide Chemical compound CC1=CC=C(S(=O)(=O)NN)C=C1 ICGLPKIVTVWCFT-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 125000003367 polycyclic group Chemical group 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- KYVBNYUBXIEUFW-UHFFFAOYSA-N 1,1,3,3-tetramethylguanidine Chemical compound CN(C)C(=N)N(C)C KYVBNYUBXIEUFW-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 2
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 2
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 2
- 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- CNXMDTWQWLGCPE-UHFFFAOYSA-N ditert-butyl-(2-phenylphenyl)phosphane Chemical compound CC(C)(C)P(C(C)(C)C)C1=CC=CC=C1C1=CC=CC=C1 CNXMDTWQWLGCPE-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 125000004043 oxo group Chemical group O=* 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 238000005086 pumping Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 125000003003 spiro group Chemical group 0.000 description 2
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N 1-ethenoxybutane Chemical compound CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- RHXHGRAEPCAFML-UHFFFAOYSA-N 7-cyclopentyl-n,n-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(C3CCCC3)C(C(=O)N(C)C)=CC2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 RHXHGRAEPCAFML-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- UXKCLTPQRBKROC-UHFFFAOYSA-N C(C)(C)C1=C(C(=CC(=C1)C(C)C)C(C)C)C1=CC=CC=C1.[P] Chemical group C(C)(C)C1=C(C(=CC(=C1)C(C)C)C(C)C)C1=CC=CC=C1.[P] UXKCLTPQRBKROC-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical class COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229950001573 abemaciclib Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000006264 debenzylation reaction Methods 0.000 description 1
- WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- SACNIGZYDTUHKB-UHFFFAOYSA-N ditert-butyl-[2-[2,4,6-tri(propan-2-yl)phenyl]phenyl]phosphane Chemical group CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C(C)(C)C)C(C)(C)C SACNIGZYDTUHKB-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 125000005948 methanesulfonyloxy group Chemical group 0.000 description 1
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- UZWDCWONPYILKI-UHFFFAOYSA-N n-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine Chemical compound C1CN(CC)CCN1CC(C=N1)=CC=C1NC1=NC=C(F)C(C=2C=C3N(C(C)C)C(C)=NC3=C(F)C=2)=N1 UZWDCWONPYILKI-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 229960004390 palbociclib Drugs 0.000 description 1
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- ZNZJJSYHZBXQSM-UHFFFAOYSA-N propane-2,2-diamine Chemical compound CC(C)(N)N ZNZJJSYHZBXQSM-UHFFFAOYSA-N 0.000 description 1
- 238000004537 pulping Methods 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229950003687 ribociclib Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000005951 trifluoromethanesulfonyloxy group Chemical group 0.000 description 1
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一种吡啶并嘧啶类衍生物的制备方法及其中间体。具体而言,本发明属于药物化学领域,本发明涉及一种式I所示化合物的及利用该中间体制备吡啶并嘧啶类衍生物的方法,该方法提高了反应产率、简单易操控、利于工业扩大生产。
Description
技术领域
本发明属于药物化学领域,涉及一种制备吡啶并嘧啶类衍生物的中间体,其制备方法及利用该中间体制备吡啶并嘧啶衍生物的方法。
背景技术
近几年各大公司分别开发一系列选择性CDK4/CDK6抑制剂,分别是Pfizer和Onyx制药公司的palbociclib、Eli Lilly的abemaciclib及Novartis的ribociclib,用于治疗癌症,心血管障碍及炎症等疾病。
WO2014183520公开一种新型结构的选择性CDK4/CDK6抑制剂,并发现具有此类结构的化合物表现出优异的效果和作用,特别是优异的药代吸收活性。具有如下结构:
文中给出如下具体化合物的制备方法,即利用硝基引入氨基而获得中间体6c化合物,进而获得目标化合物,但其产物质量(如纯度)较差,工艺路线收率也不够理想,且反应条件如Pd/C也不适合工业化生产,
发明内容
本发明提供一种式I所示化合物,
其中,为单键或双键;R1选自C1-6烷基或烷基类氨基保护基,所述C1-6烷基任选进一步被一个或多个卤素、羟基或C3-6环烷基的取代基所取代,所述烷基类氨基保护基选自苄基、2,4-二甲氧基苄基、对甲氧基苄基;R2或R3选自氢原子。
进一步地,所述式I所示化合物为:
式I所示化合物可以方便用于制备式II所示化合物,
其中,为单键或双键;R4选自氢原子或C1-6烷基;R5选自氢原子、C1-6烷基或-C(O)R7;R6选自氢原子、C1-6烷基或C3-6环烷基;R7选自氢原子或C1-6烷基,R1-R3如前述所述。
本发明还提供一种式I所示化合物在式II所示化合物的原料药、药物制剂的有关物质检查时作为杂质对照品的用途。
进一步地,本发明所述式II化合物可为但不限于:
在优选实施方案中,式II所示化合物为:
本发明还提供了制备式I所示化合物的方法,包括:式I-A所示化合物与式I-B所示化合物反应的步骤,
其中,为单键或双键;R1-R3如前述所述,X选自Cl、Br、I、-OS(O)2烷基、-OS(O)2芳基。在非限制性实施方案汇总,所述反应在碱性条件下,任选在催化剂作用下进行得式I所示化合物,所述催化剂选自金属钯、金、铁、铜、镍、铂中的至少一种,优选自金属钯、铜或者其配合使用;所述的反应溶剂选自四氢呋喃、二氧六环、N,N-二甲基乙酰胺、N,N-二甲基甲酰胺、乙腈中的至少一种;所述碱选自叔丁醇锂、叔丁醇钠、叔丁醇钾、碳酸钾、碳酸钠、磷酸钾,磷酸钠、Et3N、DBU(1,8-二氮杂二环十一碳-7-烯)、TMG(四甲基胍)、Py、DIPEA(N,N-二异丙基乙胺)中的至少一种。
进一步地,所述反应中还含有膦配体,所述膦配体选自X-phos(2-二环己基磷-2,4,6-三异丙基联苯)、t-BuXPhos(2-二-叔丁膦基-2',4',6'-三异丙基联苯)、RuPhos(2-二环己基磷-2',6'-二异丙氧基-1,1'-联苯)、SPhos(2-二环己基膦-2′,6′-二甲氧基-联苯)、DavePhos(2-二环己膦基-2'-(N,N-二甲胺)-联苯)、JohnPhos(2-(二叔丁基膦)联苯)、dppf(1,1'-双(二苯基膦)二茂铁)、dppp(1,3-双(二苯基膦)丙烷)、PPh3(三苯基磷)。
在优选实施方案中,所述反应中还含有TosNHNH2,其中TosNHNH2可先与N-保护基哌啶酮反应,随后所得中间体再与式I-B所示化合物反应得式I所示化合物,可参照如下非限制性实施例:
在可选实施方案中,制备式I所示化合物的方法如下:
其中,X-phos(即:2-二环己基磷-2',4',6'-三异丙基联苯);所述Pd2(dba)3(即:三(二亚苄基丙酮));TosNHNH2(即:对甲苯磺酰肼);t-BuOLi(即:叔丁醇锂);dioxane(即:二氧六环)。
本发明还提供了制备式II所示化合物的方法,
包括前述制备式I化合物的方法步骤,优选还包括式I所示化合物转化为式III所示化合物的步骤,
其中,式I所示化合物转化为式III所示化合物的步骤可以为一步或多步反应,为单键或双键;R1-R3如前所述;R8为烷氧羰基氨基保护基或氢原子或C1-6烷基,所述C1-6烷基任选进一步被一个或多个卤素、羟基或C3-6环烷基的取代基所取代,所述烷氧羰基类氨基保护基优选自苄氧羰基、叔丁氧羰基、烯丙氧羰基、甲氧羰基或乙氧羰基。
在可选实施方案中,式I所示化合物转化为式III所示化合物的步骤如下:
在优选实施方案中,制备式III所示化合物步骤如下:
其中式5所示化合物转化为式7所示化合物的步骤可以为一步或多步反应。
在优选实施方案中,制备式III所示化合物步骤如下:
其中,式5化合物经脱苄基得式6化合物,苄基的脱除条件可参考《ProtectiveGroups in Organic Synthesis》,5Th.Ed.T.W.Greene&P.G.M.Wuts),并将相关内容引入本申请中。优选为在催化剂作用下,所述催化剂选自但不限于Pd/C,Pd(OH)2;式4化合物在碱性条件下得式5化合物,所述碱选自但不限于经盐酸羟胺。
进一步地,制备式II所示化合物的方法还包括式III所示化合物与式IV所示化合物反应获得式V所示化合物的步骤,
其中,为单键或双键;R1-R6、R8如前述所述;Y选自Cl、Br、I、-OS(O)2烷基、-OS(O)2芳基;R9为卤素,优选自Cl、Br。
在可选实施方案中,所述反应在碱性条件下,任选在催化剂作用下进行得式I所示化合物,所述催化剂包括但不限于4,5-双二苯基膦-9,9-二甲基氧杂蒽、三(二亚苄基丙酮)二钯、1,1′-联萘-2,2′-二苯膦、[1,1′-双(二苯基磷)二茂铁]二氯化钯、二(三苯基膦)二氯化钯、三苯基膦、二氯化钯、醋酸钯、碘化亚铜、钯/碳或兰尼镍。
所述反应溶剂为非质子性溶剂,包括但不限于二氧六环、甲苯、水、乙腈、四氢呋喃、二氯甲烷、1,2-二氯乙烷、甲醇、乙醇、正丁醇、二甲基亚砜或N,N-二甲基甲酰胺中的至少一种。
提供碱性条件的试剂包括有机碱和无机碱类,所述的有机碱类包括但不限于六甲基二硅基胺基锂、六甲基二硅基胺基钠、二异丙基胺基锂、三乙胺、吡啶、2,6-二甲基吡啶、N,N-二异丙基乙基胺、正丁基锂、叔丁醇钾或四丁基溴化铵,所述的无机碱类包括但不限于碳酸铯、碳酸钠、碳酸氢钠、碳酸钾、碳酸氢钾、氢氧化锂、氢氧化钠、氢氧化钾或氢化钠。具体反应条件可参照WO2014183520中所述,并将相关内容引入本申请中。
制备式II所示化合物的方法如下:
其中式7所示化合物转化为式12所示化合物的步骤可以为一步或多步反应。
在可选实施方案中,制备式II所示化合物的方法如下:
其中式9所示化合物转化为式12所示化合物的步骤可以为一步或多步反应。在可选实施方案中,制备式II所示化合物的方法如下:
在可选实施方案中,制备式II所示化合物的方法如下:
其中,式8所示化合物为
本发明还提供了一种制备式II所示化合物可药用盐的方法,包括由前述制备方法获得式II所示化合物后,再与酸成盐的步骤,所述的酸优选为羟乙基磺酸。在非限制实例中制备方法包括:
在优选实施例中,制备式II所示化合物可药用盐的方法包括:
其中,由式11化合物与羟乙基磺酸制备式13的步骤可以为一步或多步反应,优选为一步反应。
本发明还提供了由上述的方法得到的式II所示化合物或其可药用盐。
发明详述
除非有相反陈述,否则下列用在说明书和权利要求书中的术语具有下述含义。
术语“烷基”指饱和的脂肪族烃基团,包括1至20个碳原子的直链和支链基团。优选含有1至10个碳原子的烷基,更优选含有1至6个碳原子的烷基,最优选含有1至4个碳原子的烷基,最佳为甲基。非限制性实施例包括甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、仲丁基、正戊基、1,1-二甲基丙基、1,2-二甲基丙基、2,2-二甲基丙基、1-乙基丙基、2-甲基丁基、3-甲基丁基、正己基、1-乙基-2-甲基丙基、1,1,2-三甲基丙基、1,1-二甲基丁基、1,2-二甲基丁基,及其各种支链异构体等。烷基可以是取代的或未取代的,当被取代时,取代基可以在任何可使用的连接点上被取代,所述取代基优选为一个或多个以下基团,独立地选自烷基、烯基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基(-OH)、硝基(-NO2)、氰基(-CN)、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、氧代基(=O)、氨基(-NH2)、卤代烷基、羟烷基、羧基(-C(O)OH)或羧酸酯基(-C(O)O(烷基)或(环烷基))。
术语“环烷基”指饱和或部分不饱和单环或多环环状烃取代基,其包括3至20个碳原子,优选包括3至12个碳原子,更优选环烷基环包含3至10个碳原子,最优选环烷基环包含3至6个碳原子,最佳为环丙基或环戊基。多环环烷基包括螺环、稠环和桥环的环烷基。环烷基可以是任选取代的或未取代的,当被取代时,取代基优选为一个或多个以下基团,独立地选自烷基、烯基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、氧代基、氨基、卤代烷基、羟烷基、羧基或羧酸酯基。
术语“杂环烷基”指饱和或部分不饱和单环或多环环状烃取代基,其包括3至20个环原子,其中一个或多个环原子选自氮、氧或S(O)m(其中m是0至2的整数)的杂原子,但不包括-O-O-、-O-S-或-S-S-的环部分,其余环原子为碳。优选包括3至12个环原子,其中1~4个是杂原子,更优选杂环烷基环包含3至10个环原子,更优选杂环烷基环包含5至6个环原子。单环杂环烷基的非限制性实例包含吡咯烷基、哌啶基、哌嗪基、吗啉基、硫代吗啉基、高哌嗪基、吡喃基、四氢呋喃基等。多环杂环烷基包括螺环、稠环和桥环的杂环烷基。杂环烷基可以是任选取代的或未取代的,当被取代时,取代基优选为一个或多个以下基团,独立地选自烷基、烯基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、氧代基、氨基、卤代烷基、羟烷基、羧基或羧酸酯基。
术语“芳基”指具有共轭的π电子体系的6至14元全碳单环或稠合多环(也就是共享毗邻碳原子对的环)基团,优选为6至10元,更优选苯基和萘基,最优选苯基。所述芳基环可以稠合于杂芳基、杂环烷基或环烷基环上,其中与母体结构连接在一起的环为芳基环。芳基可以是取代的或未取代的,当被取代时,取代基优选为一个或多个以下基团,独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、氨基、卤代烷基、羟烷基、羧基或羧酸酯基。
术语“杂芳基”指包含1至4个杂原子、5至14个环原子的杂芳族体系,其中杂原子选自氧、硫和氮。杂芳基优选为5至10元,更优选为5元或6元,例如噻二唑基、吡唑基、噁唑基、噁二唑基、咪唑基、三唑基、噻唑基、呋喃基、噻吩基、吡啶基、吡咯基、N-烷基吡咯基、嘧啶基、吡嗪基、咪唑基、四唑基等。
术语“烷氧基”指-O-(烷基)和-O-(未取代的环烷基),其中烷基、环烷基的定义如上所述。非限制性实例包含甲氧基、乙氧基、丙氧基、丁氧基、环丙氧基、环丁氧基、环戊氧基、环己氧基等。
“药物制剂”表示含有一种或多种本文所述化合物或其生理学上/可药用的盐或前体药物与其它化学组分的混合物,以及其它组分例如生理学/可药用的载体和赋形剂。药物组合物的目的是促进对生物体的给药,利于活性成分的吸收进而发挥生物活性。
本发明所述卤素为氟、氯、溴或碘。
术语“-OS(O)2烷基”中烷基如前“烷基”定义,烷基优选含有1至6个碳原子的烷基,最优选含有1至4个碳原子的烷基,最佳为甲基。非限制性实例包括甲磺酰氧基、三氟甲磺酰氧基、六氟乙基磺酰氧基。
术语“-OS(O)2芳基”中芳基如前“芳基”定义,芳基优选为6至10元,更优选苯基和萘基,最优选苯基。非限制性实例包括对甲苯磺酰氧基、三甲基苯磺酰氧基。本发明所用物料或溶剂均可通商业途径获得,也可参照WO2014183520中方法制备获得。
本发明化合物结构是通过核磁共振(NMR)或/和质谱(MS)来确定的。NMR位移(移R以10-6(ppm)的单位给出。NMR的测定是用Bruker AVANCE-400核磁仪,测定溶剂为氘代二甲基亚砜(DMSO-d6),氘代氯仿(CDCl3),氘代甲醇(CD3OD),内标为四甲基硅烷(TMS)。
MS的测定用FINNIGAN LCQAd(ESI)质谱仪(生产商:Thermo,型号:Finnigan LCQadvantage MAX)。
具体实施方式
以下将结合实施例更详细地解释本发明,本发明的实施例仅用于说明本发明的技术方案,本发明的实质和范围并不局限于此。
实施例1
在瓶中加入化合物1(75.6g)、TsNHNH2(74.4g)、乙醇(900mL),25℃搅拌反应5h,减压蒸干溶剂得到白色固体2(142g),收率100%,直接用于下一步反应。
在瓶中依次加入Xphos(1.9g)、Pd2(dba)3(0.9g)、叔丁醇锂(20.2g)、2(39.3g),3(35.3g)、二氧六环(500mL),搅拌条件下抽换氩气三次,氩气保护下加热至110℃反应10h,加水淬灭反应,MTBE萃取,饱和食盐水洗,硫酸镁干燥,过滤蒸干后柱层析分离得到化合物4(34g),,纯度:97%,收率75%。1H-NMR(400MHz,CDCl3)δ8.61(d,J=2.0Hz,1H),7.79-7.76(dd,J=2.4and 8.4Hz,1H),7.39-7.25(m,5H),7.16(d,J=8.4Hz,1H),6.20-6.19(m,1H),5.88(s,2H),3.66(s,2H),3.22-3.20(m,2H),2.77-2.74(m,2H),2.61-2.58(m,2H),2.11(s,6H).
实施例2
在瓶中依次加入对甲苯磺酰肼(93g)、Xphos(7.63g)、Pd2(dba)3(3.7g,)、叔丁醇锂(92g)、1(95g),3(100g)、二氧六环(3.5L),搅拌条件下抽换氩气三次,氩气保护下加热至110℃反应20h,加水淬灭反应,MTBE萃取,合并有机相,饱和食盐水洗,硫酸镁干燥,过滤蒸干得4(188g),直接用于下一步。
实施例3
在瓶中加入4(180g)、盐酸羟胺(139g)、乙醇(1.2L)、水(400mL),搅拌并加热至80℃反应20h,点板显示反应完全,减压蒸去大部分乙醇,加入NaHCO3(200g)中和,二氯甲烷萃取,合并有机相,硫酸镁干燥,过滤浓缩后经柱层析得到5(74g),纯度:98%,两步总收率:70%。1H-NMR(400MHz,DMSO-d6)δ7.95(d,J=2.4Hz,1H),7.48-7.45(dd,J=2.4and 8.8Hz,1H),7.33-7.32(m,4H),7.28-7.23(m,1H),6.41(d,J=8.8Hz,1H),5.93(s,1H),5.89(s,2H),3.55(s,2H),3.01(d,J=2.8Hz,2H),2.61-2.58(m,2H),2.38(m,2H).
实施例4
在瓶中加入5(20g)、异丙醇(300mL)、钯碳(2g),搅拌下抽换氢气三次,氢化反应完全后,用硅藻土过滤旋干得到产品6(12.4g),直接用于下一步。1H-NMR(400MHz,DMSO-d6)z,1H),7.33-7.32(m,4H),7.28-7.23(mdd,J=2.4and 8.4Hz,1H),6.43(d,J=8.4Hz,1H),5.76(s,2H),3.97(br s,1H),3.23-3.19(m,2H),2.62-2.54(m,2H),1.78-1.65(m,3H).
实施例5
在瓶中加入化合物6(5.3g),异丙醇(70mL)和DCM(70mL)搅拌溶解,加入Boc酸酐(6.5g),反应完全,加入MTBE,水洗分层,合并有机相,饱和氯化钠洗,无水硫酸钠干燥,过滤,浓缩后,经柱层析得到7(7.5g),纯度:99%,两步总收率84%。1H-NMR(400MHz,DMSO-d6)δ7.76(d,J=2.4Hz,1H),7.28-7.25(dd,J=2.4and 8.4Hz,1H),6.40(d,J=8.4Hz,1H),5.72(s,2H),4.05-4.02(m,2H),2.76(m,2H),1.68-1.64(m,2H),1.44-1.33(m,11H).
实施例6
在瓶中加入5(20g)、Boc酸酐(6.5g),异丙醇(300mL)、钯碳(2g),搅拌下抽换氢气三次,氢化反应完全后,用硅藻土过滤,加入MTBE,水洗分层,合并有机相,饱和氯化钠洗,无水硫酸钠干燥,过滤,浓缩后,经柱层析得到7(12.5g),纯度:98%,收率61%
实施例7
在20L反应瓶中加入99.9g化合物7及THF,降温至0-10℃,滴加六甲基二硅基胺基锂,滴毕后,加入溶于102.8g化合物8,室温反应1.5小时,TLC检测反应完全,加入20mL饱和氯化铵溶液淬灭反应,反应液加入醋酸30g/水100ml,冰浴搅拌,有大量固体析出,冰浴搅拌30分钟,过滤,滤饼用300ml*2丙酮洗,抽干,滤饼体加入2L饱和氯化铵打浆2小时,过滤,滤饼用500ml*2水洗,200ml*2丙酮洗,干燥得到产物102.4g,收率57.82%,HPLC纯度:96%。
实施例8
在20L反应瓶中加入化合物9、正丙醇、正丁基乙烯基醚、N,N-二异丙基乙胺、醋酸钯、双(2-二苯基膦)苯醚,氩气置换3次,氩气氛围下回流搅拌反应1小时。TLC检测完全反应。停止加热,加入二氨基丙烷,自然降温至室温搅拌3小时,有大量固体析出,冰浴搅拌0.5小时,过滤,滤饼用水5L*2洗,抽干到固体892g,收率82.3%。
实施例9
在20L反应瓶中加入化合物10、醋酸,室温搅拌溶解,加水,室温搅拌反应4-4.5小时,TLC检测反应完全,加入12L乙酸乙酯,冰浴下搅拌2小时。过滤,滤饼用1L乙酸乙酯洗,抽干,50鼓风干燥10小时得到固体707g,收率85%,HPLC纯度:99.1%。
实施例10
在5L三口反应瓶中投入11(300g,0.55mol),1.92kg甲醇,搅拌均匀,将羟乙基磺酸(300g,1.92mol)和水32g溶于480g甲醇中,滴加到上述溶液中,溶液变澄清,搅拌反应3h,终止反应,过滤,调节滤液pH至弱酸性,析晶过滤,得类白色固体261g,收率:83%,HPLC纯度>98%。
Claims (14)
1.式I所示化合物,
其中,为单键或双键;R1选自C1-6烷基或烷基类氨基保护基,所述C1-6烷基任选进一步被一个或多个卤素、羟基或C3-6环烷基的取代基所取代,所述烷基类氨基保护基选自苄基、2,4-二甲氧基苄基、对甲氧基苄基;R2或R3选自氢原子。
2.根据权利要求1所述的化合物,其为:
3.式I所示化合物在制备式II所示化合物或其可药用盐中的用途,
其中,为单键或双键;R4选自氢原子或C1-6烷基;R5选自氢原子、C1-6烷基或-C(O)R7;R6选自氢原子、C1-6烷基或C3-6环烷基,所述C1-6烷基任选进一步被一个或多个卤素、羟基或C3-6环烷基的取代基所取代;R7选自氢原子或C1-6烷基,R8为烷氧羰基类氨基保护基或氢原子或C1-6烷基,所述C1-6烷基任选进一步被一个或多个卤素、羟基或C3-6环烷基的取代基所取代,所述烷氧羰基类氨基保护基优选自苄氧羰基、叔丁氧羰基、烯丙氧羰基、甲氧羰基或乙氧羰基;R2、R3如权利要求1所述。
4.式I所示化合物在式II所示化合物或其可药用盐的原料药、药物制剂的有关物质检查时作为杂质对照品的用途,
其中,为单键或双键;R2-R6、R8如权利要求3所述。
5.根据权利要求3或4所述的用途,其特征在于所述式II所示化合物为:
6.制备式I所示化合物的方法,包括:式I-A所示化合物与式I-B所示化合物反应的步骤,
其中,为单键或双键;R1-R3如权利要求1所述,X选自Cl、Br、I、-OS(O)2烷基、-OS(O)2芳基。
7.根据权利要求6所述的方法,其特征在于所述反应在碱性条件下,任选在催化剂作用下进行得式I所示化合物,所述催化剂选自金属钯、金、铁、铜、镍、铂中的至少一种,优选自金属钯、铜或者其配合使用;所述的反应溶剂选自四氢呋喃、二氧六环、N,N-二甲基乙酰胺、N,N-二甲基甲酰胺、乙腈中的至少一种;所述碱选自叔丁醇锂、叔丁醇钠、叔丁醇钾、碳酸钾、碳酸钠、磷酸钾,磷酸钠、Et3N、DBU、TMG、Py、DIPEA中的至少一种。
8.根据权利要求7所述的方法,其特征在于所述反应中还含有膦配体,所述膦配体选自X-phos、t-BuXPhos、RuPhos、SPhos、DavePhos、JohnPhos、dppf、dppp、PPh3。
9.根据权利要求6-8任意一项所述的方法,其特征在于所述式I-A所示化合物为所述I-B所示化合物为所述式I所示化合物为其中X如权利要求6所述。
10.制备式II所示化合物或其可药用盐的方法,
包括权利要求6-9任意一项所述的方法的步骤,优选还包括式I所示化合物转化为式III所示化合物的步骤,
其中,为单键或双键;R1-R3如权利要求1所述;R4-R6如权利要求3所述;R8为烷氧羰基类氨基保护基或氢原子或C1-6烷基,所述C1-6烷基任选进一步被一个或多个卤素、羟基或C3-6环烷基的取代基所取代,所述烷氧羰基类氨基保护基优选自苄氧羰基、叔丁氧羰基、烯丙氧羰基、甲氧羰基或乙氧羰基。
11.根据权利要求10所述的方法,其特征在于所述方法还包括式III所示化合物与式IV所示化合物反应获得式V所示化合物的步骤,
其中,为单键或双键;R1-R3如权利要求1所述;R4-R8如权利要求3;Y选自Cl、Br、I、-OS(O)2烷基、-OS(O)2芳基;R9为卤素,优选自Cl、Br。
12.根据权利要求10所述的方法,其特征在于所述方法为:
13.制备式II所示化合物可药用盐的方法,包括由权利要求10-12任意一所述的制备方法获得式II所示化合物后,再与酸成盐的步骤,所述的酸优选为羟乙基磺酸。
14.由权利要求10-12任意一项所述的方法得到的式II所示化合物或其可药用盐。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2017106696000 | 2017-08-08 | ||
CN201710669600 | 2017-08-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109384767A true CN109384767A (zh) | 2019-02-26 |
CN109384767B CN109384767B (zh) | 2020-05-05 |
Family
ID=65417583
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810888327.5A Active CN109384767B (zh) | 2017-08-08 | 2018-08-07 | 一种吡啶并嘧啶类衍生物的制备方法及其中间体 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109384767B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110540535A (zh) * | 2019-10-23 | 2019-12-06 | 上海再启生物技术有限公司 | 适合放大制备4-(6-氨基吡啶-3-基)取代哌啶的工艺方法 |
CN112778303A (zh) * | 2020-12-31 | 2021-05-11 | 武汉九州钰民医药科技有限公司 | Cdk4/6激酶抑制剂shr6390的制备方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101001857A (zh) * | 2002-01-22 | 2007-07-18 | 沃尼尔·朗伯有限责任公司 | 2-(吡啶-2-基氨基)-吡啶并[2,3-d]嘧啶-7-酮 |
WO2008127678A1 (en) * | 2007-04-11 | 2008-10-23 | Exelixis, Inc. | Pyrido [2, 3-d] pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer |
CN101511829A (zh) * | 2006-09-08 | 2009-08-19 | 辉瑞产品公司 | 2-(吡啶-2-基氨基)-吡啶并[2,3-d]嘧啶-7-酮的合成 |
WO2014183520A1 (zh) * | 2013-05-17 | 2014-11-20 | 上海恒瑞医药有限公司 | 吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用 |
WO2016015597A1 (en) * | 2014-07-26 | 2016-02-04 | Sunshine Lake Pharma Co., Ltd. | Compounds as cdk small-molecule inhibitors and uses thereof |
CN105622638A (zh) * | 2014-10-29 | 2016-06-01 | 广州康盛贝特医药技术有限公司 | 嘧啶或吡啶并吡啶酮类化合物及其制备方法和应用 |
WO2016124067A1 (zh) * | 2015-02-03 | 2016-08-11 | 江苏恒瑞医药股份有限公司 | 一种周期素依赖性蛋白激酶抑制剂的羟乙基磺酸盐、其结晶形式及制备方法 |
-
2018
- 2018-08-07 CN CN201810888327.5A patent/CN109384767B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101001857A (zh) * | 2002-01-22 | 2007-07-18 | 沃尼尔·朗伯有限责任公司 | 2-(吡啶-2-基氨基)-吡啶并[2,3-d]嘧啶-7-酮 |
CN101511829A (zh) * | 2006-09-08 | 2009-08-19 | 辉瑞产品公司 | 2-(吡啶-2-基氨基)-吡啶并[2,3-d]嘧啶-7-酮的合成 |
WO2008127678A1 (en) * | 2007-04-11 | 2008-10-23 | Exelixis, Inc. | Pyrido [2, 3-d] pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer |
WO2014183520A1 (zh) * | 2013-05-17 | 2014-11-20 | 上海恒瑞医药有限公司 | 吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用 |
WO2016015597A1 (en) * | 2014-07-26 | 2016-02-04 | Sunshine Lake Pharma Co., Ltd. | Compounds as cdk small-molecule inhibitors and uses thereof |
CN105622638A (zh) * | 2014-10-29 | 2016-06-01 | 广州康盛贝特医药技术有限公司 | 嘧啶或吡啶并吡啶酮类化合物及其制备方法和应用 |
WO2016124067A1 (zh) * | 2015-02-03 | 2016-08-11 | 江苏恒瑞医药股份有限公司 | 一种周期素依赖性蛋白激酶抑制剂的羟乙基磺酸盐、其结晶形式及制备方法 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110540535A (zh) * | 2019-10-23 | 2019-12-06 | 上海再启生物技术有限公司 | 适合放大制备4-(6-氨基吡啶-3-基)取代哌啶的工艺方法 |
CN112778303A (zh) * | 2020-12-31 | 2021-05-11 | 武汉九州钰民医药科技有限公司 | Cdk4/6激酶抑制剂shr6390的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN109384767B (zh) | 2020-05-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6639551B2 (ja) | Tlr7アゴニストとして使用されるピロロピリミジン化合物 | |
CA3036594C (en) | Alkynyl-substituted heterocyclic compound, preparation method thereof and medical use thereof | |
CN109310671B (zh) | 布鲁顿酪氨酸激酶抑制剂 | |
EP3112364A1 (en) | 2,4-disubstituted phenylene-1,5-diamine derivatives and applications thereof, and pharmaceutical compositions and pharmaceutically acceptable compositions prepared therefrom | |
KR102073181B1 (ko) | 광학적으로 순수하고 임의로 치환된 2-(1-히드록시-알킬)-크로멘-4-온 유도체의 제조방법 및 약제 제조에 있어서의 그의 용도 | |
JP6474736B2 (ja) | アルビシジン誘導体、その使用および合成 | |
CN108033964B (zh) | 一种吡啶基咪唑并苯并二氮杂卓丙酸酯化合物及其合成和应用 | |
CN114349714B (zh) | 一种二苯并二氮卓衍生物及其制备方法和应用 | |
JP7347852B2 (ja) | 重水素化大環状化合物の調製方法 | |
JP2020097526A (ja) | 複素環化合物 | |
CN102875537A (zh) | 一种新的抗血栓药物的制备方法 | |
CN109384767B (zh) | 一种吡啶并嘧啶类衍生物的制备方法及其中间体 | |
WO2023179068A1 (zh) | 药物中间体及合成方法、异喹啉类衍生物及其合成方法 | |
AU2012229859B2 (en) | Nitrogen-containing saturated heterocyclic compound | |
CN112313207B (zh) | 一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用 | |
CN115135646B (zh) | 取代的多环化合物及其药物组合物和用途 | |
CN113248474A (zh) | 五元氮唑杂环衍生物及其制备方法和用途 | |
CA2730071A1 (fr) | Derives anticancereux, leur preparation et leur application en therapeutique | |
JP2022510736A (ja) | 大環状化合物とその使用 | |
CN116284018A (zh) | 一种呋喃并[2,3-b]喹啉衍生物的制备方法及其应用 | |
CN113717165A (zh) | 新型三环芳香杂环化合物,及其制备方法、药物组合物和应用 | |
CN109384727B (zh) | 酞嗪酮类化合物、其制备方法、药物组合物及用途 | |
EP3242881A1 (en) | Furoquinolinediones as inhibitors of tdp2 | |
KR20220020951A (ko) | Cdk 키나제 억제제 | |
CN115141204B (zh) | 一种萘[1,2-b]呋喃-4,5-二酮衍生物其制备及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |